Acacia Research Corporation — Q2 2016 Form 10-Q
Business and period: Acacia’s subsidiaries acquire, license, and enforce patent rights, generally sharing licensing proceeds with patent owners. This unaudited report covers the three and six months ended June 30, 2016; comparisons are with the same 2015 periods.
Financial performance and position
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $41.4 million | $40.3 million | $66.1 million | $74.5 million |
| Operating income (loss) | $(34.9) million | $1.0 million | $(44.6) million | $(12.6) million |
| Net loss attributable to Acacia | $(40.6) million | $(3.7) million | $(50.5) million | $(16.8) million |
| Basic and diluted loss per share | $(0.81) | $(0.08) | $(1.01) | $(0.35) |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $37.8 million | $(6.4) million |
- Margins and expenses: Q2 operating costs and expenses were $76.3 million, including a $40.2 million patent impairment charge. Six-month operating costs were $110.7 million. Patent amortization was $21.5 million for the half, down 18% year over year; general and administrative expense was $15.5 million, down 23%.
- Cash and liquidity: At June 30, cash and cash equivalents were $139.8 million, restricted cash $14.0 million, and short-term investments $32.2 million. Combined cash, restricted cash, and investments were approximately $186.1 million. Working capital, including restricted cash, was $165.6 million.
- Balance sheet and debt: Total liabilities were $29.8 million and stockholders’ equity $266.6 million. The company reported no long-term debt. Operating lease commitments totaled $4.6 million.
- Cash flow detail: Six-month investing cash outflow was $33.2 million, including net purchases of available-for-sale investments and $1.0 million of patent investments. Financing cash outflow was $0.025 million; no dividends were paid in the 2016 period.
Material changes and management commentary
- Q2 revenue increased 3%, but six-month revenue declined 11%. For the half, agreements fell to 19 from 43, while average revenue per agreement rose to $3.5 million from $1.7 million. Management attributes revenue variability to agreement timing, portfolio mix, negotiations, litigation, and trial outcomes.
- The $40.2 million impairment, primarily the remaining carrying value of the Adaptix portfolio, reflected lower expected future cash flows and management’s decision to stop allocating resources to certain portfolios. It drove the substantially larger quarterly and year-to-date losses.
- Q2 included $1.2 million of other operating income from reversing an attorney-fee accrual after settlement; neither party owed payment.
- Operating cash flow improved to $37.8 million from a $6.4 million use in the prior-year half, largely reflecting timing: licensee cash receipts rose to $96.0 million from $57.2 million. Receivables fell to $4.3 million from $33.5 million.
- The board terminated the dividend policy effective February 23, 2016, citing financial performance, cash needs, and alternative uses of capital. The company also adopted a tax-benefits preservation plan intended to protect potential NOLs and tax credits.
- Acacia acquired no new patent portfolios in the first half of 2016. Management reported six pending patent cases with trial dates scheduled within the next six months and expects patent legal expenses to fluctuate, potentially increasing with upcoming trials and enforcement activities.
Outlook, risks, and contingencies
- Management believes cash and anticipated operating cash flows will meet requirements through at least August 2017; it provided no specific revenue or earnings guidance. Results are described as uneven and difficult to predict.
- Revenue concentration is substantial: one licensee generated 85% of Q2 revenue and 53% of first-half revenue. Three licensees represented approximately 69%, 17%, and 10% of period-end receivables.
- Patent enforcement carries risks of adverse trial or appeal outcomes, delayed or lost licensing revenue, rising legal costs, and potential sanctions or fee awards. The company had $14.0 million of restricted cash securing a German patent-case guarantee, which may remain in place until the case is resolved under applicable law.
- Management cited difficulty sourcing suitable patent portfolios and noted that legislative and legal changes may complicate enforcement and reduce acquisition opportunities. It also disclosed operational-change risks following leadership changes and workforce reductions.
- The company recorded a $5.9 million income tax provision for Q2 and $6.1 million for the half; foreign withholding taxes and valuation allowances were key factors. It reported approximately $2.1 million of unrecognized tax benefits.
Investor verification priorities
- Assess the sustainability of revenue given licensee concentration, fewer agreements, and dependence on the timing and outcome of licensing and litigation.
- Review the assumptions underlying the $40.2 million patent impairment and remaining patent carrying value of $101.0 million.
- Verify the collection and payment timing of receivables and royalties/legal fees payable, and the availability of cash excluding restricted balances.
- Track the German guarantee, scheduled trials, litigation exposure, and possible legal-cost or sanctions developments.
- Monitor patent portfolio intake, operating-cost trends, tax asset realizability, and the company’s ability to fund operations without dividends or external financing.